Selected research
Market Analysis & Forecast
Global Blood Cancer Drugs Market Analysis and Forecast 2026-2032
Market perspective
The global Blood Cancer Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Blood Cancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Blood Cancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Blood Cancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Blood Cancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Blood Cancer Drugs include Astellas Pharma,, AstraZeneca PLC,, Bayer AG,, Bristol-Myers Squibb Company,, Celgene Corporation,, F.Hoffmann-La Roche,, AbbVie, Amgen, and Pfizer,, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Blood Cancer Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Blood Cancer Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Blood Cancer Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Blood Cancer Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Blood Cancer Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Blood Cancer Drugs revenue, projected growth trends, production technology, application and end-user industry.
Blood Cancer Drugs Segment by Company
Astellas Pharma,
AstraZeneca PLC,
Bayer AG,
Bristol-Myers Squibb Company,
Celgene Corporation,
F.Hoffmann-La Roche,
AbbVie
Amgen,
Pfizer,
Eli Lilly,
Novartis
Johnson & Johnson,
Takeda Pharmaceutical Company Ltd,
Blood Cancer Drugs Segment by Type
Blood Chemotherapy Drugs
Blood Targeted Therapy Drugs
Blood Cancer Drugs Segment by Application
lymphoma
Multiple Myeloma
Leukemia
Blood Cancer Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Blood Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Cancer Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Blood Cancer Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Blood Cancer Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Blood Cancer Drugs revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Blood Chemotherapy Drugs
- Blood Targeted Therapy Drugs
Applications
- lymphoma
- Multiple Myeloma
- Leukemia
Companies covered
- Astellas Pharma,
- AstraZeneca PLC,
- Bayer AG,
- Bristol-Myers Squibb Company,
- Celgene Corporation,
- F.Hoffmann-La Roche,
- AbbVie
- Amgen,
- Pfizer,
- Eli Lilly,
- Novartis
- Johnson & Johnson,
- Takeda Pharmaceutical Company Ltd,
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Blood Cancer Drugs Market by Type
- 1.2.1 Global Blood Cancer Drugs Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Blood Chemotherapy Drugs
- 1.2.3 Blood Targeted Therapy Drugs
- 1.3 Blood Cancer Drugs Market by Application
- 1.3.1 Global Blood Cancer Drugs Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 lymphoma
- 1.3.3 Multiple Myeloma
- 1.3.4 Leukemia
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Blood Cancer Drugs Market Dynamics
- 2.1 Blood Cancer Drugs Industry Trends
- 2.2 Blood Cancer Drugs Industry Drivers
- 2.3 Blood Cancer Drugs Industry Opportunities and Challenges
- 2.4 Blood Cancer Drugs Industry Restraints
3 Global Growth Perspective
- 3.1 Global Blood Cancer Drugs Market Perspective (2021-2032)
- 3.2 Global Blood Cancer Drugs Growth Trends by Region
- 3.2.1 Global Blood Cancer Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Blood Cancer Drugs Market Size by Region (2021-2026)
- 3.2.3 Global Blood Cancer Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Blood Cancer Drugs Revenue by Players
- 4.1.1 Global Blood Cancer Drugs Revenue by Players (2021-2026)
- 4.1.2 Global Blood Cancer Drugs Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Blood Cancer Drugs Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Blood Cancer Drugs Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Blood Cancer Drugs Key Players Headquarters & Area Served
- 4.4 Global Blood Cancer Drugs Players, Product Type & Application
- 4.5 Global Blood Cancer Drugs Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Blood Cancer Drugs Market CR5 and HHI
- 4.6.3 2025 Blood Cancer Drugs Tier 1, Tier 2, and Tier 3
5 Blood Cancer Drugs Market Size by Type
- 5.1 Global Blood Cancer Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Blood Cancer Drugs Revenue by Type (2021-2032)
- 5.3 Global Blood Cancer Drugs Revenue Market Share by Type (2021-2032)
6 Blood Cancer Drugs Market Size by Application
- 6.1 Global Blood Cancer Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Blood Cancer Drugs Revenue by Application (2021-2032)
- 6.3 Global Blood Cancer Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Astellas Pharma,
- 7.1.1 Astellas Pharma, Company Information
- 7.1.2 Astellas Pharma, Business Overview
- 7.1.3 Astellas Pharma, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
- 7.1.4 Astellas Pharma, Blood Cancer Drugs Product Portfolio
- 7.1.5 Astellas Pharma, Recent Developments
- 7.2 AstraZeneca PLC,
- 7.2.1 AstraZeneca PLC, Company Information
- 7.2.2 AstraZeneca PLC, Business Overview
- 7.2.3 AstraZeneca PLC, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
- 7.2.4 AstraZeneca PLC, Blood Cancer Drugs Product Portfolio
- 7.2.5 AstraZeneca PLC, Recent Developments
- 7.3 Bayer AG,
- 7.3.1 Bayer AG, Company Information
- 7.3.2 Bayer AG, Business Overview
- 7.3.3 Bayer AG, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
- 7.3.4 Bayer AG, Blood Cancer Drugs Product Portfolio
- 7.3.5 Bayer AG, Recent Developments
- 7.4 Bristol-Myers Squibb Company,
- 7.4.1 Bristol-Myers Squibb Company, Company Information
- 7.4.2 Bristol-Myers Squibb Company, Business Overview
- 7.4.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
- 7.4.4 Bristol-Myers Squibb Company, Blood Cancer Drugs Product Portfolio
- 7.4.5 Bristol-Myers Squibb Company, Recent Developments
- 7.5 Celgene Corporation,
- 7.5.1 Celgene Corporation, Company Information
- 7.5.2 Celgene Corporation, Business Overview
- 7.5.3 Celgene Corporation, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
- 7.5.4 Celgene Corporation, Blood Cancer Drugs Product Portfolio
- 7.5.5 Celgene Corporation, Recent Developments
- 7.6 F.Hoffmann-La Roche,
- 7.6.1 F.Hoffmann-La Roche, Company Information
- 7.6.2 F.Hoffmann-La Roche, Business Overview
- 7.6.3 F.Hoffmann-La Roche, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
- 7.6.4 F.Hoffmann-La Roche, Blood Cancer Drugs Product Portfolio
- 7.6.5 F.Hoffmann-La Roche, Recent Developments
- 7.7 AbbVie
- 7.7.1 AbbVie Company Information
- 7.7.2 AbbVie Business Overview
- 7.7.3 AbbVie Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
- 7.7.4 AbbVie Blood Cancer Drugs Product Portfolio
- 7.7.5 AbbVie Recent Developments
- 7.8 Amgen,
- 7.8.1 Amgen, Company Information
- 7.8.2 Amgen, Business Overview
- 7.8.3 Amgen, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
- 7.8.4 Amgen, Blood Cancer Drugs Product Portfolio
- 7.8.5 Amgen, Recent Developments
- 7.9 Pfizer,
- 7.9.1 Pfizer, Company Information
- 7.9.2 Pfizer, Business Overview
- 7.9.3 Pfizer, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
- 7.9.4 Pfizer, Blood Cancer Drugs Product Portfolio
- 7.9.5 Pfizer, Recent Developments
- 7.10 Eli Lilly,
- 7.10.1 Eli Lilly, Company Information
- 7.10.2 Eli Lilly, Business Overview
- 7.10.3 Eli Lilly, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
- 7.10.4 Eli Lilly, Blood Cancer Drugs Product Portfolio
- 7.10.5 Eli Lilly, Recent Developments
- 7.11 Novartis
- 7.11.1 Novartis Company Information
- 7.11.2 Novartis Business Overview
- 7.11.3 Novartis Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
- 7.11.4 Novartis Blood Cancer Drugs Product Portfolio
- 7.11.5 Novartis Recent Developments
- 7.12 Johnson & Johnson,
- 7.12.1 Johnson & Johnson, Company Information
- 7.12.2 Johnson & Johnson, Business Overview
- 7.12.3 Johnson & Johnson, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
- 7.12.4 Johnson & Johnson, Blood Cancer Drugs Product Portfolio
- 7.12.5 Johnson & Johnson, Recent Developments
- 7.13 Takeda Pharmaceutical Company Ltd,
- 7.13.1 Takeda Pharmaceutical Company Ltd, Company Information
- 7.13.2 Takeda Pharmaceutical Company Ltd, Business Overview
- 7.13.3 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
- 7.13.4 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Product Portfolio
- 7.13.5 Takeda Pharmaceutical Company Ltd, Recent Developments
8 North America
- 8.1 North America Blood Cancer Drugs Revenue (2021-2032)
- 8.2 North America Blood Cancer Drugs Revenue by Type (2021-2032)
- 8.2.1 North America Blood Cancer Drugs Revenue by Type (2021-2026)
- 8.2.2 North America Blood Cancer Drugs Revenue by Type (2027-2032)
- 8.3 North America Blood Cancer Drugs Revenue Share by Type (2021-2032)
- 8.4 North America Blood Cancer Drugs Revenue by Application (2021-2032)
- 8.4.1 North America Blood Cancer Drugs Revenue by Application (2021-2026)
- 8.4.2 North America Blood Cancer Drugs Revenue by Application (2027-2032)
- 8.5 North America Blood Cancer Drugs Revenue Share by Application (2021-2032)
- 8.6 North America Blood Cancer Drugs Revenue by Country
- 8.6.1 North America Blood Cancer Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Blood Cancer Drugs Revenue by Country (2021-2026)
- 8.6.3 North America Blood Cancer Drugs Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
9 Europe
- 9.1 Europe Blood Cancer Drugs Revenue (2021-2032)
- 9.2 Europe Blood Cancer Drugs Revenue by Type (2021-2032)
- 9.2.1 Europe Blood Cancer Drugs Revenue by Type (2021-2026)
- 9.2.2 Europe Blood Cancer Drugs Revenue by Type (2027-2032)
- 9.3 Europe Blood Cancer Drugs Revenue Share by Type (2021-2032)
- 9.4 Europe Blood Cancer Drugs Revenue by Application (2021-2032)
- 9.4.1 Europe Blood Cancer Drugs Revenue by Application (2021-2026)
- 9.4.2 Europe Blood Cancer Drugs Revenue by Application (2027-2032)
- 9.5 Europe Blood Cancer Drugs Revenue Share by Application (2021-2032)
- 9.6 Europe Blood Cancer Drugs Revenue by Country
- 9.6.1 Europe Blood Cancer Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Blood Cancer Drugs Revenue by Country (2021-2026)
- 9.6.3 Europe Blood Cancer Drugs Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
10 China
- 10.1 China Blood Cancer Drugs Revenue (2021-2032)
- 10.2 China Blood Cancer Drugs Revenue by Type (2021-2032)
- 10.2.1 China Blood Cancer Drugs Revenue by Type (2021-2026)
- 10.2.2 China Blood Cancer Drugs Revenue by Type (2027-2032)
- 10.3 China Blood Cancer Drugs Revenue Share by Type (2021-2032)
- 10.4 China Blood Cancer Drugs Revenue by Application (2021-2032)
- 10.4.1 China Blood Cancer Drugs Revenue by Application (2021-2026)
- 10.4.2 China Blood Cancer Drugs Revenue by Application (2027-2032)
- 10.5 China Blood Cancer Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Blood Cancer Drugs Revenue (2021-2032)
- 11.2 Asia Blood Cancer Drugs Revenue by Type (2021-2032)
- 11.2.1 Asia Blood Cancer Drugs Revenue by Type (2021-2026)
- 11.2.2 Asia Blood Cancer Drugs Revenue by Type (2027-2032)
- 11.3 Asia Blood Cancer Drugs Revenue Share by Type (2021-2032)
- 11.4 Asia Blood Cancer Drugs Revenue by Application (2021-2032)
- 11.4.1 Asia Blood Cancer Drugs Revenue by Application (2021-2026)
- 11.4.2 Asia Blood Cancer Drugs Revenue by Application (2027-2032)
- 11.5 Asia Blood Cancer Drugs Revenue Share by Application (2021-2032)
- 11.6 Asia Blood Cancer Drugs Revenue by Country
- 11.6.1 Asia Blood Cancer Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Blood Cancer Drugs Revenue by Country (2021-2026)
- 11.6.3 Asia Blood Cancer Drugs Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Blood Cancer Drugs Revenue (2021-2032)
- 12.2 SAMEA Blood Cancer Drugs Revenue by Type (2021-2032)
- 12.2.1 SAMEA Blood Cancer Drugs Revenue by Type (2021-2026)
- 12.2.2 SAMEA Blood Cancer Drugs Revenue by Type (2027-2032)
- 12.3 SAMEA Blood Cancer Drugs Revenue Share by Type (2021-2032)
- 12.4 SAMEA Blood Cancer Drugs Revenue by Application (2021-2032)
- 12.4.1 SAMEA Blood Cancer Drugs Revenue by Application (2021-2026)
- 12.4.2 SAMEA Blood Cancer Drugs Revenue by Application (2027-2032)
- 12.5 SAMEA Blood Cancer Drugs Revenue Share by Application (2021-2032)
- 12.6 SAMEA Blood Cancer Drugs Revenue by Country
- 12.6.1 SAMEA Blood Cancer Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Blood Cancer Drugs Revenue by Country (2021-2026)
- 12.6.3 SAMEA Blood Cancer Drugs Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst